Replies to post #1912 on Pulmatrix Inc (PULM)

[Kabuli]

said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. "There is no imminent plan to implement a reverse stock split. Pulmatrix has several important milestones ahead of us that management believes can and should drive shareholder value. Specifically:

Pulmazole is on target for our data readout. We will announce results as soon as it is appropriate based on data review.
PUR1800 is moving forward in non-clinical safety testing with a P2a study in COPD targeted for next year.
With our partner for the US (Vectura), we are targeting a P1/2 in COPD to start around year end.